Delix Therapeutics
About Delix Therapeutics
Delix Therapeutics develops neuroplastogens, a novel class of compounds that promote neuroplasticity to enhance brain health. Their approach targets neuropsychiatric conditions by repairing neural circuits and improving mental function through safe and fast-acting treatments.
```xml <problem> Current treatments for neuropsychiatric and neurodegenerative conditions often fall short, with a significant percentage of patients exhibiting resistance or experiencing only partial symptom relief. There remains a substantial unmet need for novel therapeutics that can effectively address the underlying structural and functional deficits in the brain associated with these disorders. </problem> <solution> Delix Therapeutics is developing neuroplastogens, a novel class of compounds designed to promote neuroplasticity and enhance brain health. These therapeutics aim to repair neural circuits and improve mental function by directly influencing the brain's ability to grow and form new connections. Delix's approach focuses on inducing selective neuroplasticity to rewire specific neural circuits affected by neuropsychiatric conditions. The company is developing a diversified pipeline of neuroplastogens with the potential to address a range of neuropsychiatric and neurodegenerative indications. </solution> <features> - Novel class of compounds (neuroplastogens) designed to promote neuroplasticity. - Focus on repairing neural circuits and improving mental function. - Induces selective neuroplasticity to rewire precise neural circuits. - Pipeline includes over 1500 compounds based on more than 10 unique chemical scaffolds. - Targets a range of neuropsychiatric and neurodegenerative indications. </features> <target_audience> The primary target audience includes individuals suffering from neuropsychiatric and neurodegenerative conditions, as well as clinicians and researchers seeking novel therapeutic interventions for these disorders. </target_audience> ```
What does Delix Therapeutics do?
Delix Therapeutics develops neuroplastogens, a novel class of compounds that promote neuroplasticity to enhance brain health. Their approach targets neuropsychiatric conditions by repairing neural circuits and improving mental function through safe and fast-acting treatments.
Where is Delix Therapeutics located?
Delix Therapeutics is based in Boston, United States.
When was Delix Therapeutics founded?
Delix Therapeutics was founded in 2019.
How much funding has Delix Therapeutics raised?
Delix Therapeutics has raised 108500000.
- Location
- Boston, United States
- Founded
- 2019
- Funding
- 108500000
- Employees
- 40 employees
- Major Investors
- U.S. Department of Defense